Related Experiment Video

Updated: Jun 18, 2026

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.7K

Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL

David O'Connor1,2, Melvin Joy3, Amir Enshaei3

  • 1UCL Cancer Institute, University College London, London, United Kingdom.

Blood Advances
|October 12, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.1K

Related Experiment Videos

Last Updated: Jun 18, 2026

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.7K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY.

Blood advances·2026

Paediatric therapeutic development workshop on osteosarcoma.

British journal of cancer·2026

Paediatric therapeutic development workshop on medulloblastoma.

British journal of cancer·2026

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

British journal of cancer·2026

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

British journal of haematology·2026

Single cell transcriptional evolution of myeloid leukemia of Down syndrome.

Nature communications·2026

Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma.

Blood advances·2026

Induction intensity in transplant-eligible primary CNS lymphoma: no survival benefit despite increased toxicity.

Blood advances·2026

Grip strength is associated with overall survival in myelodysplastic syndrome.

Blood advances·2026

Advancing mortality risk prediction in sickle cell disease through multi-task deep learning models.

Blood advances·2026

A CRISPR-Based Humanized Model Reveals Cooperative Role of STAG2 Loss in Familial GATA2-Deficient MDS Progression.

Blood advances·2026

Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas.

Blood advances·2026

Daily adaptive 1.5 T MR-Linac image-guided re-irradiation for prostate cancer: an international retrospective experience.

Clinical and translational radiation oncology·2026

Friday again: Timing and referral patterns of acute radiotherapy in a tertiary supraregional care network.

Clinical and translational radiation oncology·2026

Radiosensitization effects of BaTiO₃ and gold nanoparticles in proton therapy of pancreatic tumors: A Monte Carlo study.

Iranian journal of basic medical sciences·2026

Exploring the renoprotective effects of umbelliferone in rats subjected to ischemia/reperfusion injury.

Iranian journal of basic medical sciences·2026

Improving deep learning organ segmentation accuracy in cone-beam CT-guided radiotherapy using a robust scatter suppression method.

Physics and imaging in radiation oncology·2026

Associations between reported atrial fibrillation burden and cardiac substructure dosimetric variables in patients receiving thoracic radiotherapy for malignancies involving the thorax: a systematic review and meta-analysis.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us